HomeAI · summaries
Storia in 3 fonti
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for its top-selling | With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain a label expansion for its top-selling product, dwarfism drug Voxzogo.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
BioMarin notches win in study that could expand use of top-selling medicine
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.
- ·
fiercepharma.com
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth, which was an uptick from…
